All In Biotech

Drug Trial Radar · NCT00484692

Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation

Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training®

Last checked: Nov 20, 2026Latest source record: Jun 11, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 779 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

779

Actual

Start

Jul 2005

Primary completion

Not stated

Study completion Jan 2007

Sponsor

Lead sponsor
Medical University InnsbruckAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background Smokers often reject drugs as smoking cessation aids. Nonpharmacological interventions are notoriously under-evaluated. Methods We conducted a randomized clinical trial in which we compared a medication, i.e., sustained-release bupropion (Zyban®; 413 subjects), at the time of the trial the most efficacious pharmacological smoking cessation aid, with an ultrashort psychotherapeutic intervention, Psychodynamic Model Training® (366 subjects), a manual-based psychodynamically oriented 1 ½ day autosuggestion training. Outcome criterion was 12-month self-reported continuous abstinence confirmed by urine cotinine levels below the level of detection (13 ng/ml) or, in an independent analysis, by exhaled carbon monoxide of 10 ppm or less at all interviews conducted at 3, 6, and 12 months.

Conditions

  • Nicotine Dependence
  • Substance Abuse
  • Substance Dependence
  • Tobacco Dependence

Interventions

  • sustained-release bupropion (Zyban(R))Drug

  • Psychodynamic Model Training (R) = PDM(R)Behavioral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemically/pharmacologically-confirmed 12-month continuous abstinence as evidenced by self-reports of nonsmoking status in all interviews (i.e., at 3, 6, and 12 months)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute for Clinical Psychology, Psychotherapy, and Health Promotion

    Graz, Styria, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.